Marjorie Bisenius, DO
Family Medicine · Omaha, NENPI 1992731574
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 46 manufacturers reported payments, led by AbbVie at 24.0% of the total. Among family medicine clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$653
- AstraZeneca$430
- Amgen$303
- Lilly USA, LLC$263
- Otsuka America Pharmaceutical, Inc.$185
- plus $2K from 40 others
What the payments were for
- Food & beverage$4,712100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,718 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $116,961 |
| MounjaroTirzepatide | 90 | $104,625 |
| EliquisApixaban | 45 | $43,682 |
| JardianceEmpagliflozin | 52 | $43,579 |
| RybelsusSemaglutide | 21 | $39,796 |
| TrulicityDulaglutide | 30 | $27,631 |
| LinzessLinaclotide | 17 | $14,890 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,289 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $12,755 |
| FarxigaDapagliflozin Propanediol | 17 | $9,972 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,872 |
| DuleraMometasone/Formoterol | 14 | $4,682 |
| PremarinEstrogens, Conjugated | 12 | $3,241 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,463 |
| Atorvastatin Calcium | 335 | $2,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $653 | $156,757111 claims |
| Lilly USA, LLCMounjaro, Trulicity | $263 | $132,257120 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $44 | $49,45264 claims |
| PfizerEliquis, Premarin | $118 | $46,92357 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $37 | $26,04446 claims |
| AbbVieLinzess, Synthroid | $1,133 | $16,93041 claims |
| AstraZenecaFarxiga | $430 | $9,97217 claims |
| MerckDulera | $156 | $4,68214 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $1,823280 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $86892 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Omaha
- Gerard StanleyOmaha$50K
- Yongge LiuOmaha$15K
- M DadaOmaha$14K
- Christopher ConnollyOmaha$12K
- Paul VanaOmaha$12K
- Stephen TetraultOmaha$11K
- James RamigOmaha$11K
- Jeffrey RappOmaha$10K
- Christine Carlson RahnOmaha$10K
- Joseph DumbaOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.